Kornimate/medical-research-clean huggingface dataset:
assessment of l-prf, nanohydroxyapatite combined with l-prf using pulpotomy in mature mandibular first molars

Conditions: Irreversible Pulpitis

Summary: clinical and radiographic assessment of l-prf, nanohydroxyapatite material combined with l-prf scaffold in vital pulp therapy. treatments in mandibular first molars with closed apices, randomized controlled trial.

pulpotomy by using 3 materials. the first group(control group ) uses hydroxyapatite material as a pulpotomy agent, and the second group uses l-prf as a pulpotomy agent. the third group uses combined material (l-prf = nano hydroxyapatite )as a pulpotomy agent .. then assesses the clinical and radiographic result of the 2 interventions group with control group

Eligibility criteria:
inclusion criteria: patients should be free from any systemic disease. patients of either gender aged from 15-30. patients will agree to the consent and will commit to a follow-up period. soft tissues around the tooth are normal with no swelling or sinus tract. the tooth is restorable tooth has signs and symptoms of irreversible pulpitis of the mature root the tooth doesn\&#39;t contain any internal or external resorption or periapical lesions. the tooth should give a positive response to the cold test. exclusion criteria: pregnant and lactating females. patients with mental disturbance. patients who could/would not participate in a 6-month follow-up. a tooth with immature roots. patients with necrotic pulp.• tooth with periapical lesions or infections. soft tissue having fistula or swelling homoeostasis after 10 minutes can not be controlled after total pulpotomy
optimization of cardiac pacing using cardiomems

Conditions: Heart Failure

Summary: this study is designed to determine if a simplified technique for cardiac device reprogramming using pulmonary artery pressure (pap) data in the acute setting holds promise to improve subjective assessments of patient quality of life (qol), objective measurements of functional capacity, and specific systolic and diastolic echocardiographic indices.

the present study is designed to determine if a simplified technique for cardiac device( crt) reprogramming using pulmonary artery pressure (pap) via implanted cardiomems device data in the acute setting holds promise to improve subjective assessments of patient quality of life (qol), objective measurements of functional capacity, and specific systolic and diastolic echocardiographic indices. the protocol requires prospective collection and analysis of echocardiographic data, subjective symptoms (minnesota living with heart failure questionnaires), and 6-minute walk distance measurements in patients with implanted biventricular pacemakers / defibrillators who are predominantly ventricularly paced, in normal sinus rhythm, have documented nyha class 3 heart failure, and have implanted pulmonary artery pressure monitors (cardiomems, st. jude medical crmd, st. paul, mn). data collection will occur at presentation (rest and with ambulation), one month post-reprogramming, and two months after evaluation and / or reprogramming.

Eligibility criteria:
inclusion criteria: 1. patients have implanted ppm, icd, or crt devices and cardiomems 2. patients can ambulate for 6 minutes and lay on a flat surface 3. patients are paced \> 95% of the time 4. patients are not in acute chf and are on a stable medication regimen 5. patients have adequate echocardiographic windows 6. patients can consent independently exclusion criteria: 1. patients with poor echocardiographic acoustical resolution. 2. patients with congenital heart disease. 3. patients with mechanical aortic or mitral valve replacements. 4. patients with significant mitral annular calcification. 5. patients with irregular heart rates: atrial fibrillation, supraventricular tachycardia, atrial premature contractions, and ventricular arrhythmia that would preclude data acquisition. 6. patients unable to remain still secondary to movement disorders or agitation. 7. inpatient status 8. patients with poorly controlled htn (sbp\>160/90
metabolomic and inflammatory effects of oral aspirin (asa) in subjects at risk for melanoma

Conditions: Melanoma (Skin)

Summary: this is an open label phase ii pilot study assessing the metabolomic and inflammatory effects of oral aspirin (asa) in human subjects at risk for melanoma.

primary objectives i. open label trial in 60 patients to assess the capacity of either of one daily dose (81, 325 mg) of sub-chronic asa administration to increase the plasma and nevus asa metabolites such as: salicylate, salicylurate, gentisic acid, and salicyl acyl glucuronide. ii. open label trial in 60 patients to assess the capacity of sub-chronic daily asa (81, 325 mg) administration to reduce levels of prostaglandin e2 (pge2) in plasma and nevi. secondary objectives i. determine whether asa increases amp-activated protein kinase (ampk) activation in nevi. ii. determine whether asa affects whole blood leukocytes or leukocyte subsets in plasma. iii. determine whether asa affects inflammatory cytokines in plasma.

Eligibility criteria:
inclusion criteria: * must have at least 2 nevi (each \>5 mm diameter) not clinically suspicious for melanoma that can be biopsied. * must be older than age 18. * must be able to receive informed consent and sign an approved consent form that conforms to federal and institutional guidelines. exclusion criteria: * the patient is a minor, under age 18. * the patient cannot speak / understand english or spanish. * the patient is pregnant or breastfeeding. * the patient is a prisoner, critically or mentally ill, or otherwise incapacitated or considered vulnerable. * the patient has history of allergic reaction to asa. * the patient has history of severe asthma. * the patient has been taking asa or any nsaid in the past 2 weeks. * the patient has been taking a blood thinner in the past 2 weeks. * the patient has history of bleeding disorder. * the patient has history of peptic ulcer disease. * the patient has had recent intense uv exposure in the past month.
oral helicobacter pylori eradication

Conditions: H. Pylori Infection

Summary: helicobacter pylori (h. pylori) is a serious health threat that infects approximately half of the global population. in addition to colonizing the stomach, h. pylori has been shown to survive in the oral microenvironment and is associated with a variety of oral diseases, gastric eradication failure, and reinfection. currently, traditional systemic antibiotic therapy has little effect on oral h. pylori, and mouthwashes available on the market for oral h. pylori eradication often contain multiple antibiotics or complex essential ingredients, which can cause unpredictable effects on the human body. therefore, there is an urgent need for a mouthwash that does not contain antibiotics and is effective against oral h. pylori. this study focuses on the eradication effect of maxpower biological antibacterial mouthwash on oral h. pylori in a population.

inclusion criteria: oral h. pylori-positive patients, verified by h. pylori saliva test (hps),aged 18-70 years visiting the outpatient clinic of changhai hospital from march 1, 2023, to august 1, 2023, were enrolled. exclusion criteria: (1) zollinger-ellison syndrome, gastric cancer, upper gastrointestinal bleeding, or active peptic ulcer; (2) the coexistence of significant concomitant illnesses, including heart diseases, renal failure, hepatic disease, previous abdominal surgery, lactation or pregnancy; and (3) not willing to participate in the study. written informed consent was obtained from all patients prior to participation in the study.

Eligibility criteria:
inclusion criteria:oral h. pylori-positive patients, verified by h. pylori saliva test (hps),aged 18-70 years visiting the outpatient clinic of changhai hospital from march 1, 2023, to august 1, 2023, were enrolled. exclusion criteria: (1) zollinger-ellison syndrome, gastric cancer, upper gastrointestinal bleeding, or active peptic ulcer; (2) the coexistence of significant concomitant illnesses, including heart diseases, renal failure, hepatic disease, previous abdominal surgery, lactation or pregnancy; and (3) not willing to participate in the study. -

Keywords: oral h. pylori eradication evaluation antibiotic-free mouthwash
evaluation of a carepartner-integrated telehealth rehabilitation program for persons with stroke

Conditions: Stroke

Summary: the objective of this study is to identify the potential benefits of a home-based, intervention designed to facilitate carepartners' roles in stroke survivor rehabilitation. stroke survivors and caregivers will participate in pairs. stroke survivors will receive constraint induced movement therapy (cimt). caregivers of stroke survivors will be randomized to traditional caregiver education or a web based intervention for the duration of stroke survivor therapy. by learning the best way to involve family members in therapy, investigators hope to decrease the harmful effects of stroke.

the objective of this study is to identify the potential benefits of a home-based, intervention designed to facilitate carepartners' roles in stroke survivor rehabilitation. stroke survivors and caregivers will participate in pairs. stroke survivors will receive constraint induced movement therapy (cimt). caregivers of stroke survivors will be randomized to traditional caregiver education or a web based intervention for the duration of stroke survivor therapy. a tablet will be provided to participants who do not have access to complete the web based intervention. all participants will be asked to complete questionnaires at the beginning of therapy, the end of therapy, and one month post therapy.

Eligibility criteria:
inclusion criteria: stroke survivors * one month to five years post ischemic or hemorrhagic event * minimal to moderate upper extremity deficits (ability to initiate wrist and finger extension) * mini-mental screening test score of greater than 24 * presence of a care partner caregivers * at least 18 years old * ability to read and write english * mini-mental screening test score of greater than 24 exclusion criteria: stroke survivors * severe cognitive deficits caregivers * significant cognitive deficits

Keywords: therapy rehabilitation caregiver
sensitivity of alternative nrl972 detection methods in healthy subjects

Conditions: Cirrhosis

Summary: the disposition of nrl972 after a 15-second intravenous injection of 2 mg nrl972 is distinctly slower in patients with hepatic cirrhosis and acute hepatitis than in healthy control subjects. nrl972 appears to be a suitable investigational marker of hepatic transporter clearance dysfunction. although the pharmacokinetics of nrl972 provide a reliable differentiation between subject groups, this approach relies on precisely timed sampling of venous blood, cautious preparation, handling and on-site storage of plasma samples, the transfer of samples to a central laboratory for analysis, and the availability of a validated assay procedure. for these reasons, there is interest in developing and validating alternative methods for determining the concentration of nrl972 in venous blood. two such methods have been developed to date, but their utility in determining nrl972 pharmacokinetics has yet to be established.


Eligibility criteria:
inclusion criteria: subjects meeting the following conditions will be eligible for enrolment: * males or females (females of non-childbearing potential or of childbearing potential while taking medically appropriate contraception) * caucasian * age: 20 to 45 years * bmi 20 - 26 kg.m-2 * healthy based on the pre-study examination * suitable veins for easy cannulation * willing and able to provide informed consent exclusion criteria: subjects of any of the following categories will be excluded from enrolment: general - all subjects * previous participation in the trial * participant in any other trial during the last 90 days * donation of blood during the last 60 days or a history of blood loss exceeding 300 ml within the last 3 months * history of any clinically relevant allergy * presence of any acute or chronic infection * presence or history of any relevant co-morbidity * resting systolic blood pressure \> 160 or \ 95 or \< 50 mmhg * clinically relevant ecg-abnormalities, prolonged qtc with \> 450 msec in males and \> 460 msec in females in particular * presence of any relevant abnormality in the laboratory safety tests, especially low haemoglobin, increased liver enzymes * positive serology for hbsag, anti hbc and anti hcv * positive hiv test * positive alcohol or urine drug test on recruitment * history of alcohol and/or drug abuse and/or daily use of \> 30 g alcohol * smoking more than 10 cigarettes/day or equivalent of other tobacco products * use of prohibited medication * suspicion or evidence that the subject is not trustworthy and reliable * suspicion or evidence that the subject is not able to make a free consent or to understand the information in this regard general - all females * positive pregnancy test * lactating * not using appropriate contraception in premenopausal women
preventing perinatal depression with an app-based cbt program

Conditions: Perinatal Depression; Disease Prevention

Summary: the goal of this clinical trial is to learn if caremom, a mobile app-based cognitive behavioral therapy program works to prevent perinatal depression among chinese mothers. the main questions the trial aims to answer are: 1. does caremom lower depression scores after an 8-week intervention? 2. does caremom lower depression scores at 6 weeks after childbirth? 3. how satisfied are participants with caremom? 4. what unfavorable events, if any, are associated with the use of caremom? researchers will compare caremom to a matched attention control (a mobile app-based program that offers participants a similar level of interaction and daily activities) to see if caremom works to prevent perinatal depression. participants will: 1. engage in the caremom program or a relaxation training program every day for 8 weeks 2. complete a series of online questionnaire tests before and after the 8-week intervention. 3. report any discomfort experienced throughout the study period.

a two-arm parallel randomised controlled trial of 290 pregnant women will be conducted at jintang county maternity and child health hospital of chengdu, china. eligible women who consent to participate in the trial will be recruited at 20-24 weeks of gestation, and randomly allocated to either the intervention group (participate in a mobile app-based 8-week cognitive behavioral therapy program, named caremom) or the control group (participate in a mobile app-based, attention-matched, 8-week relaxation training program) using a computer-generated random number. the primary outcomes are the changes in edinburgh postnatal depression scale (epds), patient health questionnaire-9 (phq-9) and 7-item generalized anxiety disorder (gad-7) scores from from enrollment to the end of intervention at 8 weeks.

Eligibility criteria:
inclusion criteria: * aged 18-45 years * at 20-24 weeks of gestation * at risk of depression but not experiencing severe depressive symptoms at recruitment, as indicated by an edinburgh postnatal depression scale (epds) score of between 5 and 12 * own a smartphone * are able to independently engage with the program exclusion criteria: * have serious medical conditions or pregnancy complications that may affect their psychological condition, as determined by their medical doctor * have a prior diagnosis of any mental disorders * are currently or were recently (within the past six months) receiving any kinds of psychological services or treatments * have a history of self-harm or suicide * have any suicidal thoughts in the past 12 months * experienced fetal deaths in the past 18 months

Keywords: perinatal depression cognitive behavioral therapy icbt
improving mothers for a better prenatal care trial barcelona

Conditions: Intrauterine Growth Restriction; Fetal Growth Retardation

Summary: high risk women for growth restricted fetuses will randomized in the second trimester into different strategies applied to the mothers: a stress reduction program based on mindfulness techniques or a nutrition interventional program based on mediterranean diet.

randomized controlled trial among women at higher risk to have a growth restricted fetus (30%) according to royal college of obstetrics and gynecology (rcog) guidelines. these high-risk women will be randomized in order to evaluate an improvement in several outcomes thanks to different strategies applied to the mothers: a stress reduction program based on mindfulness techniques or a nutrition interventional program based on mediterranean diet. main hypothesis: specific interventions improving maternal lifestyle and well being have a positive impact on pregnancy outcomes as well as on fetal growth and development. secondary hypothesis is that interventions to improve maternal lifestyle well being have a positive impact on offspring's outcome later in life, in terms of neurodevelopment and cardiovascular profile, mediated by epigenetic changes in offspring.

Eligibility criteria:
inclusion criteria: * maternal age at recruitment ≥18 years * speak spanish fluently * viable singleton non-malformed fetus * high-risk pregnancy to develop fgr. * 19-23 weeks of gestation exclusion criteria: * fetal anomalies including chromosomal abnormalities or structural malformations detected by ultrasound. * mental retardation or other mental or psychiatric disorders that impose doubts regarding the true patient´s willingness to participate in the study. * no possibility to come to additional visits.

Keywords: mindfulness mediterranean diet neurodevelopment epigenetics fetal growth restriction
study evaluating the efficacy and safety of topical diclofenac spray in osteoarthritis of the knee: trial ii

Conditions: Osteoarthritis

Summary: the objective of this study is to evaluate the efficacy and safety of tds-943 (topical diclofenac spray) compared to oral celecoxib and placebo in subjects with osteoarthritis of the knee. the main hypotheses are that tds-943 will be better than placebo and no worse than celecoxib.

this is a multicenter, outpatient, multiple-dose, placebo- and active controlled, double-blind, double-dummy parallel group, randomized (stratified by unilateral vs. bilateral knee oa) trial. the trial will enroll subjects who have been diagnosed with oa of the knee (confirmed by weight-bearing x-ray) and whose condition is in flare at baseline. subjects who qualify to enter the study will be randomized to topical tds-943 40 mg bid, oral celecoxib 200 mg qd, or placebo in a 3:2:2 ratio.

Eligibility criteria:
inclusion criteria: * males or females in generally good health at least 40 years of age * osteoarthritis (oa) of at least one knee, verified by a weight-bearing radiograph * subject has taken an oral nsaid or analgesic at least 3 days during the past 30 days to treat knee oa pain exclusion criteria: * females who are pregnant or lactating or who may become pregnant * hypersensitivity (exacerbations of asthma, rhinitis, or urticaria) to sulfonamides, acetaminophen, diclofenac, celecoxib, aspirin, or any other nsaid * history of myocardial infarction, congestive heart failure, stroke, coronary-artery bypass graft surgery, or any other significant cardiovascular disease, or is on any form of anticoagulation therapy other than low-dose aspirin (no more than 325 mg/day)
effectiveness and tolerance of cicaplast baume b5 after superficial co2 laser resurfacing

Conditions: Wound Heal

Summary: this monocentric, double-blinded, randomized with intra-individual comparisons study is an interventional cosmetic study. the objective is to evaluate the effectiveness of a new formulation on the re-epithelialization kinetic after superficial co2 laser dermabrasion in comparison to an untreated area.

this clinical trial is conducted in accordance with the protocol, the helsinki declaration (1964) and subsequent amendments, and the international council on harmonisation (ich) good clinical practice (gcp), and in compliance with applicable regulatory requirements. statistical method: analysis will be performed using r software version 4.0.2. or higher. all statistical tests will be two-sided and at the 5% level of significance. normality tests will be at the 1% level of significance (shapiro-wilk). all efficacy evaluation will be done on the per protocol set. the categorical variables are summarized by frequency and percentage for each response category (n, %). the continuous variables are summarized using means, medians, minimum, maximum, and standard deviations for the data collected at each visit. sample size determination: a number of 22 subjects would allow to detect a significant difference of at least of 2 days for complete re-epithelialization score between the treated and untreated areas with a power of 91% at a risk alpha of 0.05 and assuming a common standard deviation of ±2.7 days. twenty-five (25) subjects will be included in the study to take into account possible dropouts.

Eligibility criteria:
inclusion criteria: * phototype ii and iii on the fitzpatrick scale * subjects with normal clinical examination and medical history compatible with the study exclusion criteria: * subject with underlying pathology that may interfere with the interpretation of the study results (dermatological history of psoriasis, eczema, urticaria... or suspicion/history of allergies to cosmetics), skin abnormality (scars, excessive hair growth, tattoos...) in the test areas (back, midline), systemic pathology * subject with excessive exposure to natural (sun) or artificial (tanning salon) ultraviolet light (uv) 4 weeks prior to the initial visit or who anticipates such exposure during the study * subject who has taken systemic treatment for more than 5 days in the month prior to inclusion

Keywords: re-epithelialization superficial co2 laser resurfacing cicaplast baume b5
corrections of anterior imbalances by posterior instrumentation and osteotomies

Conditions: Arthrodesis

Summary: several deformities of the spine exist such as the anterior imbalance. these deformities can generate functional discomfort and limit the patient's quality of life. in the event of severe trunk imbalance and progression of the deformity, operative correction of the spinal deformity by instrumentation and posterior arthrodesis may be indicated. surgical techniques and instrumentation have evolved over the past 5 years. these changes in surgical strategies have a potential impact on the patient's quality of life and the correction results in the medium and long term. the aim of the study is to analyze the surgical corrections obtained by transpedicular osteotomy and radiological changes over time with classic 2-rod techniques versus modern 4-rod instrumentation techniques


Eligibility criteria:
inclusion criteria: * major subjects\> 18 years old * subject operated at hus between 01/01/2010 to 31/12/2020 * subject with a surgical indication for arthrodesis and surgical correction of anterior imbalance by transpedicular osteotomy * subject not having expressed his opposition, after information, to the reuse of his data for the purposes of this research. exclusion criteria: * subject having expressed opposition to participating in the study * subject under guardianship or guardianship * subject under safeguard of justice

Keywords: arthrodesis degenerative lumbar scoliosis scoliosis spinal dysmorphism